Articles

Podcasts

Videos

Rheumatology

Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.

The therapy targets both IL-12 and IL-23 cytokines offering a new option for children 6 years and older living with active psoriatic arthritis. 

Ustekinumab Becomes First FDA-Approved Biologic for Pediatric Psoriatic Arthritis

Patients with psoriatic arthritis (PsA) who have elevated interleukin-23 (IL-23) levels have been linked to higher rates of depression, anxiety, and disease activity.

Elevated IL-23 Levels in PsA Patients are Associated with Depression, Anxiety

Novartis announces the EC expanded on the approval of secukinumab in EU to include pediatric patients with childhood arthritic conditions: juvenile idiopathic arthritis, enthesitis-related arthritis, and juvenile psoriatic arthritis.

Phase 3 Secukinumab Data Supports EC Approval for Patients with JIA, ERA, JPsA

Dr. Philip Mease explains that it's a good time to be treating psoriatic arthritis after results from a clinical trial show that guselkumab provided continuous improvement across measures of health-related quality of life.

Philip Mease, MD: Achieving Goals in Psoriatic Arthritis Treatment

With guselkumab, patients with active psoriatic arthritis achieved efficacy that was sustained through a 2 year clinical trial. Results show that the treatment offered continuous improvement across measures of health-related quality of life.

Philip Mease, MD: Guselkumab Addresses the Complexities of Treating Psoriatic Arthritis

Data from 2 studies evaluating adults with active psoriatic arthritis were announced today in preparation for EULAR 2022. The different population groups who received treatment were biologic-naive patients and TNF-inadequate responders.

New Promising Phase 3 Bimekizumab Data Among Patients with Psoriatic Arthritis

Furthermore, psoriatic treatment did not appear to significantly reduce COVID-19 vaccine efficacy.

Psoriatic Treatment Does Not Increase Risk of COVID-19 Infection

Patients with psoriatic arthritis and ankylosing spondylitis experienced rapid pain reduction with upadacitinib, regardless of treatment history.

Upadacitinib Improves Pain Associated with Ankylosing Spondylitis, PsA

John Tesser, MD, closes the discussion with unmet needs in the PsA treatment landscape, as well as what he hopes to see in the future. 

Unmet Needs and Future Directions for Psoriatic Arthritis

Expert panelists share tips for boosting patient compliance among patients with psoriatic arthritis.

Patient Compliance and Step Edits in Psoriatic Arthritis Management

On the HCPLive psoriatic arthritis page, resources on the topics of medical news and expert insight into PsA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on arthritis, and more.

Psoriatic Arthritis

Latest News